Stay up-to-date with the latest advances in advanced breast cancer with our expert summary from the San Antonio Breast Cancer Symposium (SABCS) 2018 Congress, 3—8 December 2018.
Professor Stephen Johnston (The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London) reviews the most pertinent emerging data presented at the SABCS 2018 Congress and discusses their potential impact on everyday clinical practice.
The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with breast cancer.
After watching this touchCONGRESS Webinar, you should be able to:
- Recognize the challenges physicians face in the management of advanced breast cancer, with a focus on HR+/HER2- disease.
- Be aware of key clinical data presented at SABCS 2018 for advanced breast cancer, including CDK4/6 inhibitors and other targeted therapies, with a focus on efficacy, tolerability, quality of life and any prognostic factors for their use (both patient and disease).
- Understand the impact that these data may have for optimizing clinical practice and patient outcomes, with a focus on treatment sequencing.
Where are we now with the current management of HR+/HER2- advanced breast cancer? Focus on challenges for optimizing treatment sequencing.
What new data for CDK4/6 inhibitors were presented at SABCS 2018? Focus on efficacy and securing optimal cancer care.
What other breaking data with novel therapies for advanced breast cancer were presented at SABCS 2018? Focus on the future treatment landscape.
Please feedback on this touchCONGRESS Webinar on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).
Watch a series of internationally renowned clinical specialists from Europe and Japan discuss key clinical data for advanced breast cancer from SABCS 2018 and their potential implications for optimizing patient outcomes, from both global and regional perspectives.Watch Now